You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR DABIGATRAN ETEXILATE MESYLATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DABIGATRAN ETEXILATE MESYLATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01976507 ↗ Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Completed Boehringer Ingelheim Phase 4 2013-10-01 The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures.
NCT01976507 ↗ Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Completed Vanderbilt University Phase 4 2013-10-01 The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures.
NCT01976507 ↗ Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Completed Vanderbilt University Medical Center Phase 4 2013-10-01 The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DABIGATRAN ETEXILATE MESYLATE

Condition Name

Condition Name for DABIGATRAN ETEXILATE MESYLATE
Intervention Trials
Healthy 3
Healthy Subjects 1
Pharmacokinetics 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DABIGATRAN ETEXILATE MESYLATE
Intervention Trials
Pancreatitis 1
Thromboembolism 1
Atrial Flutter 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DABIGATRAN ETEXILATE MESYLATE

Trials by Country

Trials by Country for DABIGATRAN ETEXILATE MESYLATE
Location Trials
United States 5
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DABIGATRAN ETEXILATE MESYLATE
Location Trials
Florida 2
Texas 1
Arizona 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DABIGATRAN ETEXILATE MESYLATE

Clinical Trial Phase

Clinical Trial Phase for DABIGATRAN ETEXILATE MESYLATE
Clinical Trial Phase Trials
Phase 4 1
Phase 1 4
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DABIGATRAN ETEXILATE MESYLATE
Clinical Trial Phase Trials
Completed 4
Unknown status 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DABIGATRAN ETEXILATE MESYLATE

Sponsor Name

Sponsor Name for DABIGATRAN ETEXILATE MESYLATE
Sponsor Trials
Huons Co., Ltd. 1
Huons Co.,Ltd. 1
Mayo Clinic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DABIGATRAN ETEXILATE MESYLATE
Sponsor Trials
Industry 6
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.